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Liver ﬁbrosis occurs as a wound-healing scar response following acute and chronic liver inﬂammation including alcoholic liver
disease, non-alcoholic steatohepatitis, hepatitis B and C, and autoimmune hepatitis. Myoﬁbroblasts, mainly transdiﬀerentiated
from hepatic stellate cells, are pivotal cell types that produce ﬁbrillar collagen. The activation of inﬂammatory cells, including
Kupﬀer cells, is a crucial step for activating hepatic stellate cells. Toll-like receptors (TLRs) are pattern recognition receptors that
sense pathogen-associated molecular patterns (PAMPs), which discriminate the products of microorganisms from the host. TLRs
are expressed on Kupﬀer cells, endothelial cells, dendritic cells, biliary epithelial cells, hepatic stellate cells, and hepatocytes in the
liver. TLR signaling induces potent innate immune responses in these cell types. The liver is constantly exposed to PAMPs, such as
LPS and bacterial DNA through bacterial translocation because there is a unique anatomical link, the portal vein system between
liver and intestine. Recent evidence demonstrates the role of TLRs in the activation of hepatic immune cells and stellate cells
during liver ﬁbrosis. Moreover, crosstalk between TLR4 signaling and TGF-β signaling in hepatic stellate cells has been reported.
This paper highlights the role of TLR signaling in stellate cell activation and the progression of liver ﬁbrosis.
1.Introduction
Liver ﬁbrosis is a wound healing scar response following
acute and chronic liver diseases including chronic hepatitis B
and C, autoimmune hepatitis, nonalcoholic steatohepatitis,
and alcoholic liver disease [1, 2]. The pathohistological
ﬁndings of liver cirrhosis, the endstage of liver ﬁbrosis, show
hepatocellular death, a lobular inﬂammatory cell inﬁltrate,
excessive deposition of extracellular matrix (ECM) protein,
and the appearance of regenerative nodules that may result
in liver failure, portal hypertension, and hepatocellular
carcinoma [1, 2]. Thus, wound healing scar response in
the liver represents a harmful response rather than a
beneﬁcial response in liver regeneration. Liver ﬁbrosis is
highly associated with chronic hepatocellular injury and
subsequent inﬂammatory response that produces inﬂamma-
tory cytokines and recruits inﬂammatory leukocytes into the
injured site. This inﬂammatory circumstance in the liver
drives the activation of hepatic stellate cells (HSCs) through
various ﬁbrogenic mediators including TGF-β and PDGF
[1, 2]. Activated HSCs transdiﬀerentiate into myoﬁboblasts,
which then produce excessive ECM proteins, including
collagen type I, III, and IV. This leads to an irreversible
collagen deposition, resulting in liver ﬁbrosis [1, 2].
Lipopolysaccharide (LPS, also known as endotoxin)
levels in systemic and portal vein blood are increased
in patients with cirrhosis [3, 4]. LPS is a Gram-negative
bacterial cell wall component that binds to the pattern
recognition receptor, Toll-like receptor (TLR) 4 with its
coreceptors MD-2 and CD14, transmits the signals through
adaptor proteins MyD88, TIRAP, TRIF, and TRAM to
activate the kinases, IRAK1, IRAK4, TAK1, JNK, and IKK.
These intracellular kinases lead to the activation of the
transcription factors NF-κB, AP-1, and interferon regulatory
factors (IRFs) resulting in the induction of potent innate
immune responses [5]. Kupﬀer cells, resident macrophages
in the liver, are known to respond to LPS through TLR4 to
produce various inﬂammatory cytokines including TNF-α,
IL-1β, IL-6, IL-12, IL-18, and chemokines in granulomatous
liver disease, ischemia/reperfusion liver injury, nonalcoholic2 Gastroenterology Research and Practice
steatohepatitis, and alcoholic liver disease [6–8]. HSCs,
central cell types in liver ﬁbrosis, also express high levels
of TLR4 [9, 10]. A unique anatomical link, the portal vein
system between the liver and intestines, may allow for the
exposure of bacterial products, including LPS and bacterial
DNA, to the liver [11]. However, the hepatic immune
response is strictly regulated to avoid a harmful response
in physiological conditions [11, 12]. In addition, sterile
inﬂammation may provide endogenous TLR ligands for the
activationofdangersignalsinducingﬁbrogenicresponse[7].
This paper summarizes the role of TLR signaling in HSC
activation and liver ﬁbrosis.
2.TLRSignalinginHepaticStellateCells
HSCs are located in the space of Disse in the normal
liver. Quiescent HSCs are primary cell types that store
large amounts of Vitamin A-containing lipid droplets in the
human body [1]. Activated HSCs are the major source of
ECM protein in the ﬁbrotic liver. Following liver injury,
HSCs are activated by various ﬁbrogenic stimuli, including
TGF-β and PDGF, and inﬂammatory cytokines that are
mainly produced from Kupﬀer cells [1, 2]. After activa-
tion, HSCs lose Vitamin A-containing lipid droplets and
transdiﬀerentiate into myoﬁbroblasts that highly express α-
smooth muscle actin (SMA). The excessive production and
deposition of ECM proteins cause hepatic ﬁbrosis [2]. We
havedemonstratedthatactivatedhumanHSCsexpressTLR4
and its coreceptors MD-2 and CD14 [9]. LPS treatment
induces the strong activation of NF-κB and JNK/AP-1
pathways in activated HSCs. LPS enhances expression of
the adhesion molecules ICAM-1 and VCAM-1 on the cell
surface, and induces the secretion of chemokines, IL-8
and MCP-1 in activated HSCs. LPS-induced IL-8 secretion
is completely blocked by inhibiting NF-κB activation and
partially inhibited by JNK inactivation, indicating the critical
role of NF-κB and JNK in TLR4 signaling of HSCs.
Recently, our study demonstrated that TLR4 upregulates the
expression of various types of chemokine (MCP-1, MIP-
1α,M I P - 1 β, RANTES, KC, MIP-2, and IP-10) and TLR2,
and it downregulates the expression of bone morphogenetic
protein (BMP) and activin membrane bound inhibitor
(Bambi), a transmembrane suppressor of TGF-β signaling
[10, 13]. Bambi is a type I TGF-β receptor that lacks an
intracellular kinase domain and acts as an inhibitor of
BMP, activin and TGF-β signaling. Overexpression of Bambi
inhibits, while a dominant negative form of Bambi enhances,
TGF-β signaling in HSCs [10]. Thus, TLR4-mediated Bambi
downregulation augments TGF-β signaling in HSCs.
Although the ligands for TLR3 and TLR4 stimulate
HSCs to induce IFN-β production through adaptor TRIF in
macrophages [5], HSCs could produce IFN-β in response
to the ligand for TLR3, but not TLR4, suggesting unique
TLR3/TLR4-TRIF signaling pathways in HSCs, which might
be distinct from those in macrophages [14].
HSCs express TLR2, a receptor for Gram-positive bacte-
rial cell wall components, such as peptidoglycan and lipote-
ichoic acid [5, 15]. HSCs barely respond to TLR2 ligands.
Pretreatment of TNF-α or IL-1β signiﬁcantly upregulates
TLR2 expression in HSCs. This primes HSCs to increase
NF-κB activation and IL-8 production in response to TLR2
ligands [16]. LPS also upregulates TLR2 expression in
HSCs [10], suggesting that the initiation by inﬂammatory
mediators such as TNF-α,I L - 1 β, and LPS might be required
for fulﬁlling TLR2 signaling in HSCs.
TLR9 that recognizes bacteria-derived, unmethylated
CpG-containing DNA, is expressed in HSCs [17]. Watanabe
et al. has demonstrated that host-derived denatured DNA
from apoptotic hepatocytes induces a diﬀerentiation of
HSC via TLR9 [17]. Apoptotic hepatocyte DNA induces
ﬁbrogenic responses with the elevation of mRNA levels of
TGF-β and collagen type I in HSCs. In addition, apop-
totic hepatocyte-derived DNA inhibits PDGF-induced HSC
chemotaxis through TLR9 and MyD88 [17].
3. TLR4 Signalingin LiverFibrosis
The activation of both HSCs and Kupﬀer cells that express
TLR4 is associated with the progression of liver ﬁbrosis.
TLR4-mutant mice have less liver inﬂammation and ﬁbrosis
thanTLR4-wild-typemicefollowingbileductligation(BDL)
and chronic treatment of carbon tetrachloride (CCl4), or
thioacetamide[10].MicedeﬁcientinCD14andLPS-binding
protein also show decreased cholestasis-induced liver ﬁbrosis
[18]. These results suggest a strong contribution of LPS-
TLR4interactioninthedevelopmentofliverﬁbrosis.Indeed,
systemic plasma LPS levels are signiﬁcantly elevated in
these three mouse models of experimental liver ﬁbrosis
[10, 19, 20], suggesting that intestinal microﬂora-derived
LPS translocates into the liver through the portal vein
by increased intestinal permeability following liver injury.
We have tested the contribution of intestinal microﬂora
in liver ﬁbrosis. Mice were orally treated with a cocktail
of nonabsorbable broad-spectrum antibiotics (ampicillin,
neomycin, metronidazole, and vancomycin) for 4 weeks
prior to induction of liver ﬁbrosis [10, 21]. This antibiotic
cocktail successfully reduced plasma LPS levels after BDL,
leading to a signiﬁcant attenuation of liver inﬂammation
and ﬁbrosis [10]. Thus, intestinal microﬂora-derived and
translocated LPS participate in TLR4-mediated liver ﬁbrosis,
most likely due to increased intestinal permeability induced
by intestinal dysbiosis, such as bacterial overgrowth, and
disintegrity in the tight junction of intestinal epithelium.
TLR4 is also activated by endogenous ligands, such as
HMGB1, hyaluronan, and heat shock protein 60 [15, 22, 23].
Currently, we do not have strong evidence that endogenous
TLR4 ligands are involved in liver ﬁbrosis. Further investiga-
tion is needed.
Kupﬀer cells are well-known targets for TLR4 ligand LPS
and produce various types of inﬂammatory and ﬁbrogenic
cytokines, which may activate HSCs [6, 7]. Quiescent and
activated HSCs also express TLR4 [9, 10]. The speciﬁc roles
of TLR4 in Kupﬀer cells and HSCs during liver ﬁbrosis were
unknown. To investigate these roles, we generated TLR4-
chimeric mice by using bone marrow (BM) transplantation
(BMT) [10]. Kupﬀer cells are known as radio-resistantGastroenterology Research and Practice 3
cells [24, 25]. Thus, a standard type of BMT with whole
body irradiation insuﬃciently replaces Kupﬀer cells with
donor BM-derived cells. To resolve this problem, we have
established a new style of BM-chimera using a combination
of whole body irradiation and BMT with speciﬁc deletion
of Kupﬀer cells by liposomal clodronate injection [10].
These TLR4-chimeric mice have a successful replacement of
endogenous Kupﬀer cells with donor BM-originated Kupﬀer
cells, which contain TLR4-mutant BM-derived hematopoi-
etic cells, including Kupﬀer cells, and TLR4-wild recipient-
originated endogenous liver cells, including hepatocytes and
HSCs. Few hepatocytes induce NF-κB nucleartranslocation
in response to LPS in Kupﬀer cell-depleted mice, conﬁrming
that hepatocytes barely respond to the ligand for TLR4
compared with nonparenchymal liver cells [10, 26]. Recent
e x c l u s i v es t u d i e sh a v ec o n ﬁ r m e dt h a tH S C sa r en o tB M
derived[27,28].Asmentionedabove,KupﬀercellsandHSCs
are direct targets of LPS in vitro and in vivo [6, 9, 10].
The speciﬁc roles of TLR4 in Kupﬀer cells and HSCs were
discriminated by this TLR4-chimera system. In this study,
the mice with TLR4-mutant endogenous liver cells exhibited
a signiﬁcant reduction of liver ﬁbrosis, and the mice with
TLR4-wild endogenous liver cells had a suﬃcient degree of
ﬁbrosis in the liver after BDL [10]. These ﬁndings indicate
that the recipient-originated endogenous liver cells, but not
donor-derived BM cells including Kupﬀer cells, are crucial
cell types that respond to TLR4 ligands in liver ﬁbrosis.
4.CrosstalkbetweenTLR4 Signalingand
TGF-β SignalinginStellateCellActivation
There are at least two roles of TLR4 signaling in HSCs.
First, TLR4-stimulated HSCs produce various chemokines
and express adhesion molecules (ICAM-1, VCAM-1, and
E-selectin) to recruit Kupﬀer cells and/or circulating
macrophages by the site of HSCs. Indeed, conditioned
mediumproducedfromLPS-treatedHSCsincreasedKupﬀer
cell migration and adhesion [10]. Second, the activation of
TLR4 signaling enhances TGF-β signaling in HSCs [10].
HSCs isolated from collagen promoter-driven GFP trans-
genic (Coll-GFP) mice increase GFP intensity when collagen
promoter activity is increased [29]. TGF-β treatment alone
slightly increased collagen promoter activity in quiescent
HSCs whereas LPS pretreatment further increased TGF-β-
induced collagen promoter activity in HSCs. These ﬁndings
suggested that TLR4 signaling enhances TGF-β signaling in
HSCs [10]. We then tested the role of Kupﬀer cells in HSC
activation by co-cultured Coll-GFP HSCs with Kupﬀer cells.
Coll-GFP HSCs cocultured with Kupﬀer cells increased GFP
expression, which was further augmented by LPS pretreat-
ment, suggesting that TLR4 signaling enhances Kupﬀer cell-
mediated HSC activation [10]. Coll-GFP HSCs co-cultured
with TLR4-mutant Kupﬀer cells express a similar level of
GFP expression to the HSCs co-cultured with wild-type
Kupﬀer cells after LPS stimulation. Thus, TLR4 on Kupﬀer
cellshasaminorroleforTLR4-mediatedHSCactivation,but
KupﬀercellsarerequiredforHSCactivationastheimportant
source of TGF-β because HSC activation was completely
abolished by treatment with a TGF-β inhibitor in co-culture
of Kupﬀer cells and HSCs.
Comprehensive microarray analysis demonstrated that
Bambi, a transmembrane TGF-β receptor inhibitor, was
downregulated in HSCs after LPS stimulation, whereas other
TGF-β signaling associated genes (TGF-β receptor, Smad
family, SNoN, Ski, and Sara) were unchanged [10, 13].
Quiescent HSCs, but not Kupﬀer cells and hepatocytes,
express high levels of Bambi in the liver. Importantly,
Bambi expression is suppressed in in vivo activated HSCs
isolated from mice after BDL or chronic CCl4 treatment
whereas HSCs isolated from bile duct ligated-TLR4-mutant
mice have unchanged levels of Bambi expression [10].
We suggest that high levels of Bambi expression restrict
TGF-β signaling in HSCs of normal livers. Upon TLR4
stimulation Bambi expression is quickly decreased. Then,
TGF-β signaling becomes free from the restriction by Bambi
topromoteﬁbrogenicresponse.Interestingly,HSCsactivated
in culture do not downregulate Bambi expression. Thus,
Bambi downregulation is an important feature of HSC acti-
vation in vivo. One study clearly demonstrated that human
Bambi inhibits TGF-β-induced Smad3 phosphorylation,
and silencing endogenous Bambi enhances TGF-β reporter
activity [30]. The study further revealed that Bambi interacts
with Smad7, interfering with the complex composed of
type I and type II TGF-β receptors, and Smad3, resulting
in inhibiting TGF-β signaling. In addition, Harada et al.
demonstratedthatBambiexpressioninbiliaryepithelialcells
is downregulated during epithelial-mesenchymal transition
(EMT), suggesting an additional role of Bambi as a marker
for EMT [31].
TLR4 signaling activates NF-κB and JNK/AP-1 pathways
through MyD88 and TRIF [15]. TLR4-mediated downreg-
ulation of Bambi expression requires the activation of NF-
κB and partially JNK through MyD88, but not TRIF, in
HSCs. Indeed, Bambi expression was downregulated in WT
and TRIF−/− HSCs, but not in MyD88−/−,N F - κB, or JNK
inactivated HSCs after LPS stimulation (E.S. unpublished
observation) [10]. Similarly, MyD88−/−,b u tn o tT R I F −/−,
micedemonstratedreducedﬁbrogenicgeneexpressionatthe
early phase after BDL, whereas both MyD88−/− and TRIF−/−
mice had reduced liver ﬁbrosis at the late phase of liver
ﬁbrosis [10]. These ﬁndings suggest that MyD88 is crucial
fortheBambi-regulatedliverﬁbrosis,whereasTRIFregulates
ﬁbrogenic responses independently of Bambi, at least at the
chronicstage.Takentogether,TLR4signalingiscrucialinthe
activation of HSCs during liver ﬁbrosis. Intestinal microﬂora
is a major source of LPS as a ligand for TLR4 in liver
ﬁbrosis.TLR4signalinginHSCsenhancestherecruitmentof
inﬂammatory cells and downregulates Bambi for ﬁbrogenic
response Figure 1.
5. TLR4 Polymorphism, HSCs,and
LiverFibrosis
A recent genecentric functional genome scan in patients
with chronic hepatitis C virus has identiﬁed seven single
nucleotide polymorphisms (SNPs) that may predict the risk4 Gastroenterology Research and Practice
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Figure 1: TLR4 signaling enhances TGF-β signaling in hepatic stellate cells. Upon liver injury, intestinal permeability is increased due to
the intestinal dysbiosis and tight junction disintegrity, which allows microﬂora-derived LPS into the portal vein. This LPS stimulates TLR4
on hepatic stellate cells (HSCs). Quiescent HSCs express high levels of Bambi which restricts TGF-β signaling. TLR4 stimulation leads to
the production of various chemokines (MCP-1, MIP-1β, and RANTES) in HSCs, recruiting Kupﬀer cells through their CCR1 and CCR2.
RecruitedKupﬀer cells produce TGF-β which bindstoTGF-β receptor typeI inHSCs.Simultaneously, TLR4signalingdownregulates Bambi
expression through MyD88 and NF-κB in HSCs. HSCs become free from restricted TGF-β signaling by the downregulation of Bambi, which
eventually induces HSC activation.
of developing liver cirrhosis [32, 33]. Among these seven
SNPs, a TLR4 T399I SNP is the second most predictive in
protecting the progression of liver cirrhosis. TLR4 D299G
is another TLR4 SNP. These two SNPs are associated with
a blunted response to LPS [34]. These ﬁndings conﬁrmed
the relevance of TLR4 in a large group of patients with
liver ﬁbrosis. Based on this study, Guo et al. examined the
response of HSCs with TLR4 D299G and T3991 SNPs to
LPS. TLR4 D299G and/or T3991 SNPs were reconstituted
into a human stellate cell line, LX-2 cells, and immortalized
TLR4−/− mouse HSCs (TLR4−/−mHSC) [35]. LX-2 cells or
TLR4−/−mHSCs expressing either the one or both SNPs
displayed a marked reduction of NF-κB activity and cytokine
production(MCP-1andIL-6)andunchangedBambiexpres-
sion [35]. The TLR4 SNPs inhibited HSC growth and
enhanced spontaneous HSC apoptosis [35]. These ﬁndings
demonstrated the mechanistic function of the two TLR4
SNPs in HSC activation and the risk of ﬁbrosis progression.
6. TLR3 inLiverFibrosis
TLR3recognizesdoublestrandedRNA,suchaspolyinosinic-
polycytidylic acid (poly I:C), to induce a potent innate
immune response that includes the production of inter-
feron type I and type II. TLR3 ligand poly I:C treat-
ment attenuates liver ﬁbrosis induced by the treatment ofGastroenterology Research and Practice 5
3,5-diethoxycarbonyl-1,4-dehydrocollidine (DDC) diet and
CCl4 [36]. This ﬁbrosis reduction by poly I:C is NK cell
dependent and IFN-γ dependent. NK cells stimulated with
poly I:C induce the cytotoxicity to activated HSCs, but not
quiescent HSCs. Poly I:C directly, and indirectly through
IFN-γ, enhances TRAIL expression in NK cells, and this
increases the cytotoxicity of NK cells against activated HSCs,
resulting in the suppression of liver ﬁbrosis. The research
group further demonstrated that poly I:C-dependent NK
cell-dependent suppression of liver ﬁbrosis is inhibited in
ethanol-treated animals [37]. These ﬁndings suggest that the
reduction of TLR3-mediated NK cell-dependent HSC killing
is one of the mechanisms underlying the enhancement of
liver ﬁbrosis in alcoholic liver disease.
7. TLR9 inLiverFibrosis
TLR9 recognizes bacteria-derived unmethylated CpG rich
DNA [5]. A recent report from our group clearly suggests
that liver ﬁbrosis progression is associated with intestinal
microﬂora-derived products and their translocation [10].
Previous studies have shown that patients and animals with
cirrhosis have increased bacterial DNA levels in their plasma
and ascites [38, 39]. On the other hand, Watanabe et al.
demonstrated that denatured host origin DNA from dying
hepatocytes stimulates HSCs through TLR9 in liver ﬁbrosis.
TLR9−/− mice showed a reduction of liver ﬁbrosis after BDL
and chronic CCl4 treatment [17, 40]. These ﬁndings suggest
that both bacterial DNA and host denatured DNA derived
fromdyingcellsparticipateintheprogressionofliverﬁbrosis
as a ligand for TLR9.
Recently, Connolly et al. have demonstrated the contri-
bution of TLR9 and CD11c-expressing cells to liver ﬁbrosis
[41]. CD11c is expressed on dendritic cells (DCs) and some
monocytes and macrophages [42]. They used the model of
liver ﬁbrosis induced by thioacetamide plus leptin treatment
as a similar pathophysiology to CCl4 models. Depletion of
CD11c-expressing cells using CD11c-DTR mice signiﬁcantly
reduced liver ﬁbrosis, suggesting the importance of CD11c-
expressing non-parenchymal liver cells in the progression of
liver ﬁbrosis [41]. CD11c-expressing cells from ﬁbrotic liver
increased the capacity to produce TNF-α, IL-6, and various
chemokines, which were further increased by TLR9 ligand
stimulation in CD11c-expressing cells of ﬁbrotic livers, but
not of normal livers. This increased sensitivity of ﬁbrotic
liver CD11c-positive cells to TLR ligands was induced only
by the ligand for TLR9, not TLR3, TLR4, or TLR5. CpG-
DNA-primed ﬁbrotic liver CD11c-positive cells increased
NK cell cytotoxicity and cytokine production, including
IFN-γ in a TNF-α dependent manner [41]. CpG-DNA-
primed ﬁbrotic liver CD11c-positive cells induced HSC
proliferation and production of inﬂammatory mediators,
such as IL-1α, IL-6, and MCP-1. This study demonstrated
the important features of TLR9 and DCs in liver ﬁbrosis
using CD11c-depleted mice. However, the studies for DCs
in liver ﬁbrosis are still incomplete. Further studies are
needed to clarify the role of DCs in the progression of liver
ﬁbrosis.
8. TAK1 inLiverFibrosis
TAK1 is a MAP3K which is activated by the signaling of
TLRs, IL-1 receptor, TNF receptor, and TGF-β receptor
[43, 44]. TAK1 is an upstream kinase of both IKK/NF-κB
and JNK/AP-1 pathways [15]. The NF-κB pathway regulates
the expression of antiapoptotic genes, such as Bcl-2, Bcl-
xL, A20, iNOS, c-FLIP, IAPs, and TRAF family molecules,
to block death receptor-mediated or mitochondria-mediated
hepatocytes death [45]. NF-κB also prevents prolonged
JNK activation. Prolonged JNK activation induces phos-
phorylation of the E3 ligase Itch and subsequent ubiq-
uitination and degradation of caspase-8 inhibitor c-FLIP,
which accelerates hepatocyte apoptosis [46]. Thus, NF-κB
protects hepatocytes from apoptosis whereas JNK promotes
apoptosis. Therefore, we could not predict whether TAK1
tends to induce or protect from hepatocyte apoptosis.
As expected, neither NF-κB nor JNK activation following
TNF-α stimulation occurred in TAK1−/− hepatocytes [47].
Surprisingly, TAK1−/− hepatocytes increased the sensitivity
to TNF-α-induced cell death. More surprisingly, sponta-
neous hepatocyte death occurred in hepatocyte speciﬁc
TAK1−/− mice [47]. These mice display spontaneous liver
injury, inﬂammation, and ﬁbrosis at the age of one month
and develop hepatocellular carcinoma at the age of nine
months [47, 48]. These results suggest that spontaneous
persistent hepatocyte death occurs in hepatocyte speciﬁc
TAK1−/− mice, and these dying hepatocytes release alarmins
which stimulate both Kupﬀer cells and HSCs, resulting in
liver inﬂammation and ﬁbrosis Figure 2. These ﬁndings are
evidence that liver ﬁbrosis and carcinogenesis are associated
with persistent hepatocyte injury and inﬂammation without
any carcinogens. Hepatocyte speciﬁc TAK1−/− mice will be
great animal models for addressing the role of the interplay
between ﬁbrosis and hepatocellular carcinoma.
9. Conclusion
While patients with mild to moderate liver ﬁbrosis may
not show clinical symptoms, liver cirrhosis is a major
cause of morbidity and mortality. Recent advanced studies
demonstrated the strong evidence of the role of TLR
signaling in liver ﬁbrosis. A number of issues concerning
the role of TLRs for HSC activation and liver ﬁbrosis still
need to be addressed. First, although we have shown the
evidence that intestinal microﬂora promotes liver ﬁbro-
genesis due to bacterial translocation, we still need to
address the mechanism of bacterial translocation in liver
ﬁbrosis, which includes changes in microbiome composition
and disintegrity of intestinal tight junction. Second, the
studies for the endogenous TLR ligands which promote
HSC activation have not been completed. Very recently,
mitochondrial DNA has been reported as an endogenous
TLR9 ligand [49], which might be an endogenous ligand to
activate HSCs. Third, we need to address the mechanism
by which TLR signaling regulates Bambi expression and
by which Bambi regulates HSC activation. The research on
TLRs and HSCs in liver ﬁbrosis has just been started. The
future basic and translational studies will uncover additional6 Gastroenterology Research and Practice
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Figure 2: Ablation of TAK1 in hepatocytes induces spontaneous liver injury, inﬂammation, ﬁbrosis, and cancer. Spontaneous hepatocyte
death occurs in hepatocyte speciﬁc TAK1-deﬁcient mice followed by the release of damage-associated molecular patterns (DAMPs) which
stimulate Kupﬀer cells to produce TNF-α. This TNF-α further induces cell death in TAK1-deﬁcient hepatocytes lacking activation of NF-κB
and JNK. TNF-α,I L - 1 β, and IL-6 released from Kupﬀer cells cause liver inﬂammation. Kupﬀer cell-derived TGF-β stimulates hepatic stellate
cells resulting in ﬁbrogenesis. The persistent hepatocyte death and uncontrolled compensatory proliferation in the livers of hepatocyte
speciﬁc TAK1-deﬁcient mice induce the reactivation of onco-fetal liver genes that are associated with the initiation of hepatic carcinogenesis.
clinical relevance of TLRs and their related signaling in
liver ﬁbrosis. Clinically, hepatocellular carcinoma is strongly
associated with liver ﬁbrosis and cirrhosis. However, it is
still unknown whether severe liver ﬁbrosis promotes the
initiation and/or progression of hepatocellular carcinoma.
W ew i s ht oo p e nt h i sm y s t e r i o u sd o o ri nf u t u r es t u d i e su s i n g
hepatocyte speciﬁc TAK1−/− mice.
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